U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C6H12O7
Molecular Weight 196.1553
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of Gluconic Acid

SMILES

OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O

InChI

InChIKey=RGHNJXZEOKUKBD-SQOUGZDYSA-N
InChI=1S/C6H12O7/c7-1-2(8)3(9)4(10)5(11)6(12)13/h2-5,7-11H,1H2,(H,12,13)/t2-,3-,4+,5-/m1/s1

HIDE SMILES / InChI

Molecular Formula C6H12O7
Molecular Weight 196.1553
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Gluconic acid is a natural compound produced from glucose through a simple dehydrogenation reaction catalysed by glucose oxidase. Gluconic acid and its salts are used in the formulation of food, pharmaceutical and hygienic products.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P02792|||Q9BTZ8
Gene ID: 2512.0
Gene Symbol: FTL
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Ferrlecit

Approved Use

Ferrlecit is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy.

Launch Date

1999
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
12.9 μg/mL
1.5 mg/kg single, intravenous
dose: 1.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GLUCONATE ION plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
95 μg × h/mL
1.5 mg/kg single, intravenous
dose: 1.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GLUCONATE ION plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
2 h
1.5 mg/kg single, intravenous
dose: 1.5 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
GLUCONATE ION plasma
Homo sapiens
population: UNHEALTHY
age: CHILD
sex: FEMALE / MALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study.
2017-09
The available intravenous iron formulations: History, efficacy, and toxicology.
2017-06
In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress.
2010
Activation of P2X(7) receptors induced [(3)H]GABA release from the RBA-2 type-2 astrocyte cell line through a Cl(-)/HCO(3)(-)-dependent mechanism.
2002-01
Cloning of a Serratia marcescens DNA fragment that induces quinoprotein glucose dehydrogenase-mediated gluconic acid production in Escherichia coli in the presence of stationary phase Serratia marcescens.
2001-12-18
Ineffectiveness of intranasal zinc gluconate for prevention of experimental rhinovirus colds.
2001-12-01
Iron sucrose or ferric gluconate?
2001-12
Post-natal ontogeny of stanniocalcin gene expression in rodent kidney and regulation by dietary calcium and phosphate.
2001-12
An atypical chemical burn.
2001-11-03
Role of CFTR's PDZ1-binding domain, NBF1 and Cl(-) conductance in inhibition of epithelial Na(+) channels in Xenopus oocytes.
2001-11-01
Aluminium toxicity and iron homeostasis.
2001-11
Functional atrioventricular block in a preterm infant.
2001-11
Physiological characterisation of Penicillium chrysogenum strains expressing the expandase gene from Streptomyces clavuligerus during batch cultivations. Growth and adipoyl-7-aminodeacetoxycephalosporanic acid production.
2001-10
Hypocalcemia in the newborn.
2001-10
Chemical mechanism of beta-xylosidase from Trichoderma reesei QM 9414: pH-dependence of kinetic parameters.
2001-10
Considerations for optimal iron use for anemia due to chronic kidney disease.
2001-10
99mTc-labeling experiments on CCK(4) by a direct method.
2001-10
Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients.
2001-10
Lack of allergic reaction to Ferrlecit in a patient with a history of severe pruritic reaction with INFeD.
2001-10
Imaging and localization of pancreatic insulinomas.
2001-09-22
Anion modulation of the slowly activating vacuolar channel.
2001-09-15
Identification and determination of glucuronides and their aglycones in Erigeron breviscapus by liquid chromatography-tandem mass spectrometry.
2001-09-14
Bioavailability and pharmacokinetics of magnesium after administration of magnesium salts to humans.
2001-09-11
Significance of interferon-gamma in coronary artery bypass surgery.
2001-09-11
Hydrofluoric acid burn from a household rust remover.
2001-09-03
Background osmolyte current involved in cell volume regulation of neuroblastoma x glioma hybrid NG108-15 cells.
2001-09
On-line coupling of a miniaturized bioreactor with capillary electrophoresis, via a membrane interface, for monitoring the production of organic acids by microorganisms.
2001-09
Thioglucosidase activity from Sphingobacterium sp. strain OTG1.
2001-09
[Possible treatments of glottic spasm].
2001-09
Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours.
2001-09
Intraoperative ultrasound and preoperative localization detects all occult insulinomas; discussion 1025-6.
2001-09
Solubility and relative absorption of copper, iron, and zinc in two milk-based liquid infant formulae.
2001-09
CFTR modulates programmed cell death by decreasing intracellular pH in Chinese hamster lung fibroblasts.
2001-09
Water-soluble adamantane-terminated dendrimers possessing a rhenium core.
2001-08-10
Properties and modulation of alpha human atrial natriuretic peptide (alpha-hANP)-formed ion channels.
2001-08
Electricity and the treatment of hydrofluoric acid burns--the wave of the future or a jolt from the past?
2001-08
Iontophoretic delivery of calcium for experimental hydrofluoric acid burns.
2001-08
Fatal unintentional occupational poisonings by hydrofluoric acid in the U.S.
2001-08
Clinical features, tissue smear and competitive enzyme linked immunosorbent assay as dignostic and prognostic procedures for visceral leishmaniasis in Yemen.
2001-08
Excipient-excipient interaction in the design of sustained-release theophylline tablets: in vitro and in vivo evaluation.
2001-07
Cadmium in zinc-containing mineral supplements.
2001-07
Substrate selectivity of Gluconobacter oxydans for production of 2,5-diketo-D-gluconic acid and synthesis of 2-keto-L-gulonic acid in a multienzyme system.
2001-06
Single K+ channels in endocrine cells dispersed from the cricket (Gryllus bimaculatus) corpora allata.
2001-06
Effects of P5, a novel oxazolo(3,2-a)pyridine derivative with a long-acting antihypertensive activity, on different agonist-mediated pressor responses in pithed rats.
2001-04
Calcium L-edge XANES study of some calcium compounds.
2001-03-01
Novel degradable polymers combining D-gluconic acid, a sugar of vegetal origin, with lactic and glycolic acids.
2001
Development of a process for the biotechnological large-scale production of 4-hydroxyvalerate-containing polyesters and characterization of their physical and mechanical properties.
2001
Adverse reactions associated with mobile therapeutic apheresis: analysis of 17,940 procedures.
2001
Biosynthesis of poly(3-hydroxybutyrate-co-3-mercaptobutyrate) as a sulfur analogue to poly(3-hydroxybutyrate) (PHB).
2001
Multicenter randomized comparative double-blind controlled clinical trial of the safety and efficacy of zinc gluconate versus minocycline hydrochloride in the treatment of inflammatory acne vulgaris.
2001
Patents

Sample Use Guides

8 weeks of IV ferric gluconate 125 mg weekly
Route of Administration: Intravenous
In Vitro Use Guide
The effect of iron(III)-gluconate (Ferlixit) at various concentrations on the malondialdehyde production in isolated rat liver mitochondria was studied. Concentratiors of iron as low as 100 uM are able to elicit a significant enhancement of lipid peroxidation. process.
Substance Class Chemical
Created
by admin
on Mon Mar 31 17:54:00 GMT 2025
Edited
by admin
on Mon Mar 31 17:54:00 GMT 2025
Record UNII
R4R8J0Q44B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
Gluconic Acid
HSDB   INCI   MART.   MI   VANDF   WHO-DD  
INCI  
Official Name English
E-574
Preferred Name English
GLUCONIC ACID [VANDF]
Common Name English
GLUCONIC ACID, D-
Common Name English
GLUCONAL GA-50
Common Name English
GLUCONIC ACID [MART.]
Common Name English
NSC-77381
Code English
MALTONIC ACID
Common Name English
GLUCONIC ACID [MI]
Common Name English
DEXTRONIC ACID
Common Name English
INS NO.574
Code English
PENTAHYDROXYCAPROIC ACID
Systematic Name English
D-GLUCONIC ACID
Common Name English
Gluconic acid [WHO-DD]
Common Name English
GLUCONIC ACID [HSDB]
Common Name English
INS-574
Code English
Classification Tree Code System Code
DSLD 1108 (Number of products:5)
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
EPA PESTICIDE CODE 104
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
JECFA EVALUATION INS-574
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
NCI_THESAURUS C360
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
Code System Code Type Description
CHEBI
33198
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
EVMPD
SUB13980MIG
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
DRUG BANK
DB13180
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
CAS
526-95-4
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
HSDB
487
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
DRUG CENTRAL
3264
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
FDA UNII
R4R8J0Q44B
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
RXCUI
2475956
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
NCI_THESAURUS
C61777
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
MERCK INDEX
m5762
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY Merck Index
DAILYMED
R4R8J0Q44B
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
SMS_ID
100000078190
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
NSC
77381
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
EPA CompTox
DTXSID8027169
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
PUBCHEM
10690
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
WIKIPEDIA
GLUCONIC ACID
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
ECHA (EC/EINECS)
208-401-4
Created by admin on Mon Mar 31 17:54:00 GMT 2025 , Edited by admin on Mon Mar 31 17:54:00 GMT 2025
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY